What people report

Tirzepatide reviews: what people report

Read 77 people, 4 sitesPublished by PepVault

Of the 77 people whose Tirzepatide write-ups we read, 68 describe a change they wanted (58 a change in weight or appetite; 4 clearer thinking, memory or mood; 4 less pain or faster healing), 1 noticed nothing and 32 describe something unwanted.

What people report

68 of the 77 people describe at least one change they wanted. Each bar counts the people who named anything in that group, once each, out of all 77; the line under it says what they named, and how many named it. 5 of them took Tirzepatide alongside other peptides at the same time.

  • Weight and appetite58 of 77 · 75%weight loss 42 · less appetite 18 · less food noise or fewer cravings 12
  • Thinking, memory and mood4 of 77 · 5%less brain fog 2 · clearer, quicker thinking 1 · less anxiety 1
  • Pain, injury and healing4 of 77 · 5%less inflammation 4
  • Sleep2 of 77 · 3%better sleep 2
  • Energy1 of 77 · 1%more energy 1
  • Joints and tendons1 of 77 · 1%less joint pain 1
  • Gut1 of 77 · 1%a calmer gut 1
  • Other25 of 77 · 32%lower blood sugar 15 · less wish to drink or smoke 5 · a general sense it helped 2 · a lower resting heart rate 1 · fewer headaches 1 · lower cholesterol 1

What went wrong or did nothing

32 of the 77 people describe something they didn’t want, and 1 noticed nothing at all.

  • Noticed nothing at all1 of 77 · 1%
  • Gut18 of 77 · 23%nausea or an upset stomach 9 · constipation 5 · burping or wind 2 · heartburn 2 · bloating 1 · diarrhoea 1
  • Energy7 of 77 · 9%tiredness 7
  • Thinking, memory and mood3 of 77 · 4%low mood or loss of pleasure 2 · foggy thinking 1
  • Skin and hair3 of 77 · 4%a skin flare 1 · burning or tingling skin 1 · hair shedding 1
  • Sleep1 of 77 · 1%worse sleep 1
  • Pain, injury and healing1 of 77 · 1%back pain 1
  • Other9 of 77 · 12%a higher resting heart rate 3 · feeling cold 2 · low blood sugar 2 · a racing heart 1 · an emergency room visit 1 · dizziness or low blood pressure 1 · food tasting different 1 · headaches 1

Your report

Taken Tirzepatide? What did you notice?

One tap to start. About 30 seconds, no account.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking Tirzepatide? Keep your own record

Log each dose and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

When people say it begins

10 of the 77 people say when they first noticed something; 67 don’t.

  • Within a month5 of 77 · 6%
  • In the first week3 of 77 · 4%
  • On the first day2 of 77 · 3%

What people took it for

46 of the 77 people say what they took it for; 31 don’t.

  • Weight loss29 of 77 · 38%
  • Type 2 diabetes14 of 77 · 18%
  • Appetite control1 of 77 · 1%
  • Diabetes1 of 77 · 1%
  • Inflammation and sleep apnea1 of 77 · 1%

How it’s thought to work

Shown in people

Tirzepatide acts on two gut-hormone receptors at once, GLP-1 and GIP. Together they slow the stomach, make a meal fill you sooner, quiet hunger in the brain and help the pancreas release insulin when blood sugar rises. Controlled trials in people showed it lowers both body weight and blood sugar; it is approved as Mounjaro for type two diabetes and as Zepbound for weight loss and sleep apnea.

Sources: Jastreboff et al., 2022: SURMOUNT-1, weight in adults without diabetes; Frías et al., 2021: SURPASS-2, blood sugar against semaglutide

What studies show

Our research section has 19 study pages on Tirzepatide: 18 in people and 1 in mice.

The first large trial in people without diabetes gave 2539 adults a weekly shot of tirzepatide or a dummy shot for 72 weeks (SURMOUNT-1); on the highest dose their weight fell by 20.9% on average, against 3.1% on the dummy shot.

Where the reports run ahead of the studies

Weight loss, less appetite, lower blood sugar, nausea and constipation are what the controlled trials found too. Where the reports run ahead: 5 of the 77 people describe less wish to drink, which no finished controlled trial of tirzepatide has tested; studies of health records point the same way, and trials are registered (PubMed, searched November 19, 2026).

Where the reports come from

77 people on 45 pages across 4 sites, written from May 2024 to November 2026. Read on November 19, 2026.

The largest single site, the Peptide Critic forum, gave 24 of the 77 (31%).

Peptide Critic, which runs its forum, also runs a shop on its own site that sells injection pens and supplies, not peptides.

Millions of people take tirzepatide on a prescription, and the few who write on these forums are a small corner of them who chose to write. Most Peptide Critic posters took tirzepatide sold for research, and the Diabetes UK posters took Mounjaro on a prescription. On the forums we stopped at about sixty people, the limit we set for every compound.

Read and not counted

  • A rapamycin.news member who supplies it to clients: Writes of the clients they sell it to and of their results: the seller’s side of the counter, so not counted.
  • A Peptide Critic forum staff member’s posts: The same account posts the forum’s vendor sales roundups, and the site runs its own store: the seller’s side of the counter, so not counted.
  • Vendor reviews, telehealth and vial-quality threads on the Peptide Critic forum: Written about a seller, a price or a vial rather than about what the person noticed, so not counted.
  • Posts about a stack where the other drug did the work: Where a person put the change down to survodutide, cagrilintide or another drug added to tirzepatide, it is not counted here.
  • Reports about someone else (a wife, a husband, a friend, clients): Second-hand; only a person’s own report counts.
  • Posts where the drug was unclear (“these meds”, “GLP-1s”): Counted only where the person names tirzepatide, Mounjaro or Zepbound.
  • Posts with a plan, a dose question, a price or a supply question and no outcome: Most posts in these threads; nothing noticed was said, either way.
  • Drugs.com user reviews: The site refuses automated reads, so it was skipped.
  • Patient.info’s community: Searched: almost no first-person Mounjaro posts, so nothing to count.
  • LongeCity forum: Searched: no thread of members’ own tirzepatide reports, only a passing mention in an unrelated thread, not read.
  • Posts on X from clinics, providers, coaches or sellers, or with no outcome: Clinics and providers explaining it to clients, a coach, a vendor rebrand, someone in the peptide trade, news posts, and questions or plans with nothing noticed; not counted.
  • Reddit: Not part of this count.

How we counted

We read every open write-up we could find by people who took Tirzepatide, on its own page, and counted each person once however often they posted, including those who noticed nothing. Sellers, clinics, shop reviews and anyone who earns on a sale are not counted, and neither is a search result’s snippet; the list above names what we read and left out. Write-ups lean positive, because people who notice nothing rarely write about it and expecting an effect can produce one. People on X and on the forums can’t be matched to each other, so someone who wrote in both places may be counted twice.

Spot an error? feedback@pepvault.app. How we research. This page reports what people say; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking Tirzepatide? Keep your own record

Log each dose and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo